---
title: "Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295233040.md"
description: "Princeton, New Jersey on August 7, 2026 - Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical firm specializing in developing and marketing treatments for rare diseases with unmet medical requirements, shared its latest developments."
datetime: "2026-08-07T11:56:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295233040.md)
  - [en](https://longbridge.com/en/news/295233040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295233040.md)
generator: "portal-rs"
---

# Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Princeton, New Jersey on August 7, 2026 - Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical firm specializing in developing and marketing treatments for rare diseases with unmet medical requirements, shared its latest developments.

### Related Stocks

- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

- [Lifeward Sets Timeline for 2026 Shareholder Meeting](https://longbridge.com/en/news/299101843.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)
- [NVCT: Strong clinical progress and financial position drive near-term catalysts in precision medicine](https://longbridge.com/en/news/298760060.md)
- [Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases | ASND Stock News](https://longbridge.com/en/news/298966857.md)
- [Sarcomatrix Therapeutics Provides Update on Board Expansion and Rare Disease Programs](https://longbridge.com/en/news/298940181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**